BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 11861203)

  • 1. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 2. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral miltefosine in the treatment of kala-azar.
    Mohan A; Seth S
    Natl Med J India; 2000; 13(4):202-3. PubMed ID: 11002688
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miltefosine--the long-awaited therapy for visceral leishmaniasis?
    Herwaldt BL
    N Engl J Med; 1999 Dec; 341(24):1840-2. PubMed ID: 10588972
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
    Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
    Troya J; Casquero A; Refoyo E; Fernández-Guerrero ML; Górgolas M
    Scand J Infect Dis; 2008; 40(1):78-80. PubMed ID: 17852921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
    Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
    Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal leishmaniasis and miltefosine.
    Tuon FF; Amato VS
    Clin Infect Dis; 2007 Jun; 44(11):1525-6; author reply 1526-7. PubMed ID: 17479959
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 15. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
    Escobar P; Yardley V; Croft SL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
    Seifert K; Croft SL
    Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engima of therapeutic failure in visceral leishmaniasis.
    Arya SC
    J Assoc Physicians India; 1993 Mar; 41(3):155-8. PubMed ID: 8226600
    [No Abstract]   [Full Text] [Related]  

  • 19. Breakthrough in the management of visceral leishmaniasis.
    Thakur BB
    J Assoc Physicians India; 2003 Jul; 51():649-51. PubMed ID: 14621030
    [No Abstract]   [Full Text] [Related]  

  • 20. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
    Murray HW; Delph-Etienne S
    J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.